Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at the XIX International Symposium on Amyloidosis (ISA)
30 mai 2024 07h00 HE
|
Attralus, Inc
AT-02, the company’s lead pan-amyloid removal therapeutic candidate, is currently being evaluated in a Phase 1 three-part trial and a Phase 2 open label extension trial in ATTR and AL amyloidosis...
Attralus Announces First Subject Enrolled in Phase 1 Clinical Trial of AT-02, Its Lead Pan-Amyloid Removal Therapeutic Candidate
17 oct. 2022 07h00 HE
|
Attralus, Inc
SAN FRANCISCO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic...
Attralus Announces New Clinical Data in ATTR CM and AL With AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent
12 sept. 2022 07h00 HE
|
Attralus, Inc
AT-01 shows increased LV uptake and LV amyloid activity in all cardiac ATTR and AL subjects, but in none of the controls (100% accuracy)AT-01 demonstrates significantly higher left ventricular uptake...
Attralus Announces Presentation of Clinical Data for AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent, at the 18th International Symposium on Amyloidosis
08 sept. 2022 07h00 HE
|
Attralus, Inc
AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosis in multiple organsSensitivity in those with previously diagnosed cardiac disease was 100%...
Attralus Announces New Preclinical Data Demonstrating Novel Human Chimeric Antigen Receptor-Macrophages (CAR-M) for Potential Amyloid Removal at 18th International Symposium on Amyloidosis
06 sept. 2022 09h00 HE
|
Attralus, Inc
Human CAR-M cells can be generated with the pan-amyloid reactive p5 peptide as the target amyloid recognition elementThis novel system may serve as an adjunct to anti-amyloid monoclonal antibodies for...
Attralus Presents In Vivo Preclinical Data for AT-02 Demonstrating Significant Amyloid Reduction at 18th International Symposium on Amyloidosis
06 sept. 2022 07h00 HE
|
Attralus, Inc
AT-02 demonstrates amyloid reduction from the heart, kidney, liver, and spleenAT-02 induces in vivo macrophage-mediated phagocytosis of amyloid fibrilsAT-02 binds potently to multiple types of amyloid...
Attralus to Present New Data on Its Amyloidosis Portfolio at the 2022 International Symposium on Amyloidosis
22 août 2022 07h00 HE
|
Attralus, Inc
SAN FRANCISCO, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic...
Attralus Receives U.S. FDA Orphan Drug Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of Transthyretin Amyloidosis
08 août 2022 07h00 HE
|
Attralus, Inc
SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic...
Positive New Data from Phase 1/2 Trial of AT-01 (Iodine I-124 Evuzamitide) Presented at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
14 juin 2022 11h45 HE
|
Attralus, Inc
AT-01 is the first pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosisAT-01 visualizes and quantifies organ-specific changes in amyloid load over time AT-01 detected...